September 26, 2016 1:45 PM ET

Pharmaceuticals

Company Overview of Plexxikon Inc.

Company Overview

Plexxikon Inc. develops small molecule pharmaceuticals. The company develops a portfolio of preclinical and clinical stage compounds to address unmet medical needs in oncology, CNS, autoimmune and bone, and other therapeutic areas. Its pipeline comprises Zelboraf (vemurafenib), an oral and small molecule that targets the BRAF mutation, occurring in about half of all cases of melanomas; and oral and investigational agent that co-inhibits kinase targets, FMS, and Kit and oncogenic Flt3 to treat diseases. The company’s pipeline also includes agents to treat neurological diseases, including pain, multiple sclerosis, and Alzheimer's disease; agents that target to address unmet medical needs in rh...

91 Bolivar Drive

Berkeley, CA 94710

United States

Founded in 2000

Phone:

510-647-4000

Fax:

510-548-8014

Key Executives for Plexxikon Inc.

Chief Executive Officer
Co-founder, Chairman of the Board and Member of Scientific Advisory Board
Age: 71
Co-Founder and Chairman of Scientific Advisory Board
Chief Financial Officer and Vice President
Compensation as of Fiscal Year 2016.

Plexxikon Inc. Key Developments

Plexxikon Inc. and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

Plexxikon Inc. and Merck announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikon’s investigational CSF-1R inhibitor, and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression. The Phase 1/2 trial will enroll patients with advanced melanoma and multiple other solid tumors with the goal of determining the safety and tolerability of the combination therapy. The trial is expected to begin enrollment by mid-year. PLX3397 is a novel oral small molecule that potently and selectively inhibits CSF-1R, KIT, and mutant FLT3 kinases. CSF1R and KIT regulate key components of both the tumor and its microenvironment (macrophages, osteoclasts, mast cells). In addition to melanoma and other solid tumors to be studied in this collaborative trial, PLX3397 is being evaluated in several other clinical indications, including tenosynovial giant cell tumor (TGCT), historically called pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), breast cancer and glioblastoma. KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. KEYTRUDA is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Oncosec Medical Incorporated and Plexxikon Inc. Collaborate to Explore Combination Immunotherapy in Preclinical Tumor Studies

OncoSec Medical Inc. announced a preclinical collaboration with Plexxikon Inc., to test the combination of Plexxikon's selective CSF-1R inhibitor with OncoSec's Immunopulse pIL-12. Intratumoral macrophages and other related cell types, like myeloid-derived suppressor cells, can be strongly immunosuppressive and block anti-tumor immunity. Given understanding of IL-12 as a potent driver of immunogenicity and tumor-infiltrating lymphocytes (TILs) and the potential role of tumor-resident myeloid cells in suppressing the anti-tumor effects of TILs, hypothesize that blocking CSF-1R with Plexxikon's selective CSF-1R inhibitor will lead to synergistic effects in the syngeneic B16.F10 melanoma mouse model. Interleukin-12 (IL-12) is an inflammatory cytokine that is believed to be a master regulator of the immune system, and is important in the up-regulation of both the innate and adaptive immune responses. IL-12 is a key driver of the cascade of biological events which ultimately lead to T-cell-specific killing of cancer cells. Moreover, cytokines and chemokines induced by this pathway also increase the recruitment of inflammatory T-cells into tumors.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Plexxikon Inc., please visit www.plexxikon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.